Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class. The biotech had been evaluating a 200-mg weekly subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback